...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of rheumatology >B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence
【24h】

B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence

机译：系统性硬化中的B细胞耗竭疗法：实验依据和临床证据更新

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Systemic sclerosis (SSc) is a systemic rheumatic disease with poor prognosis since therapeutic options are limited. Recent evidence from animal models suggests that B-cells may be actively involved in the fibrotic process. B-cells from tight skin mice, an animal model of scleroderma, display a “hyperresponsive” phenotype; treatment with rituximab (RTX) significantly attenuates skin fibrosis in this animal model. In humans, B-cell infiltration is a prominent finding in most lung biopsies obtained from patients with SSc-associated interstitial lung disease. Several open label studies have assessed the clinical efficacy of RTX in SSc. In most patients skin fibrosis improved; lung function either improved or remained stable. Definite conclusions regarding the clinical efficacy of RTX in SSc cannot be drawn but further exploration with a multicenter, randomized study is warranted.
机译：由于治疗选择有限，系统性硬化症（SSc）是一种预后较差的系统性风湿病。来自动物模型的最新证据表明，B细胞可能积极参与了纤维化过程。紧密皮小鼠（一种硬皮病动物模型）的B细胞表现出“高反应性”表型。在该动物模型中，利妥昔单抗（RTX）治疗显着减轻了皮肤纤维化。在人类中，B细胞浸润​​是大多数从SSc相关性间质性肺疾病患者获得的肺活检中的重要发现。一些开放标签研究评估了RTX在SSc中的临床疗效。大多数患者的皮肤纤维化得到改善;肺功能改善或保持稳定。不能得出有关RTX在SSc中的临床疗效的明确结论，但是有必要通过多中心，随机研究进一步探索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号